跳至主要内容
临床试验/jRCT2031250664
jRCT2031250664招募中不适用

An open-label Phase II study to evaluate the immunogenicity and safety of CH5-HK (HPAIV_H5N1EzoRedFox)

未提供0 个研究点目标入组 70 人开始时间: 待定
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study

入排标准

年龄范围
18age 0month 0week old over 至 No limit(—)
性别
All

入选标准

  • Healthy adults aged 18 years or older who have not yet been vaccinated against the H5 subtype at the time of informed consent.

排除标准

  • Individuals who have a clear history of H5 subtype influenza (as reported by the subject)
  • Individuals who have previously experienced anaphylaxis due to food, medication or other substances
  • Individuals who have a current history of serious diseases affecting the cardiovascular, hematological, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric systems.
  • Individuals with a history of Guillain-Barre syndrome or acute disseminated encephalomyelitis
  • Individuals with confirmed influenza infection during the current season (2025/2026) (up to the first vaccination)

研究者

发起方
未提供

相似试验